Axsome Therapeutics, Inc.
AXSMDrugs in Pipeline
11
Phase 3 Programs
11
Upcoming Catalysts
3
Next Catalyst
Dec 15, 2026
37wMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
AXS-05
Agitation in Patients With Dementia of the Alzheimer's Type
AXS-12 (reboxetine)
Narcolepsy
Solriamfetol 150 mg
Excessive Sleepiness
AXS-05 (dextromethorphan and bupropion) oral tablets
Major Depressive Disorder
Solriamfetol 300 mg
Binge-Eating Disorder
AXS-07
Migraine
AXS-07 (MoSEIC meloxicam and rizatriptan)
Migraine
AXS-07 (meloxicam-rizatriptan)
Migraine
AXS-14 (Esreboxetine)
Fibromyalgia
Bupropion
Major Depressive Disorder
AXS-05 (dextromethorphan-bupropion)
Treatment Resistant Depression
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AXS-05 | Phase 3 | Agitation in Patients With Dementia of the Alzheimer's Type | - | - |
AXS-12 (reboxetine) | Phase 3 | Narcolepsy | - | - |
Solriamfetol 150 mg | Phase 3 | Excessive Sleepiness | - | - |
AXS-05 (dextromethorphan and bupropion) oral tablets | Phase 3 | Major Depressive Disorder | - | - |
Solriamfetol 300 mg | Phase 3 | Binge-Eating Disorder | - | - |
AXS-07 | Phase 3 | Migraine | - | - |
AXS-07 (MoSEIC meloxicam and rizatriptan) | Phase 3 | Migraine | - | - |
AXS-07 (meloxicam-rizatriptan) | Phase 3 | Migraine | - | - |
AXS-14 (Esreboxetine) | Phase 3 | Fibromyalgia | - | - |
Bupropion | Phase 3 | Major Depressive Disorder | - | - |
AXS-05 (dextromethorphan-bupropion) | Phase 3 | Treatment Resistant Depression | - | - |
Migraine
3 drugs in this indication
Major Depressive Disorder
2 drugs in this indication
Narcolepsy
2 drugs in this indication
Agitation in Patients With Dementia of the Alzheimer's Type
1 drug in this indication
Excessive Sleepiness
1 drug in this indication
Binge-Eating Disorder
1 drug in this indication
Treatment Resistant Depression
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)